Questionnaire Survey on Adoption and Prescription of Biosimilars (Antibody and Its-related Products) by Medical Doctors in Japan
Authors:
- 1 May 2022
- journal article
- research article
- Published by Pharmaceutical Society of Japan in YAKUGAKU ZASSHI
- Vol. 142 (5) , 547-560
Abstract
Biosimilars are less expensive than their originators, and Japanese government policies call for their development and promotion. However, the adoption and prescription of some biosimilars, especially antibody/its-related ones, have been delayed for use in Japan, possibly due to concerns on the differences in quality attributes such as glycan structures between the originators and their biosimilars, and that clinical efficacy/safety studies are conducted for usually one disease and its results extrapolated to other indications. We conducted a questionnaire survey among physicians in four disease areas (hematology, medical oncology, rheumatoid arthritis, and inflammatory bowel disease), where biosimilars of antibody/its-related drugs have been approved, regarding their thoughts on the adoption and prescription of biosimilars in Japan from January to April 2020. We received totally 1,024 responses. When adopting biosimilars and explaining them to patients, physicians requested specific information including the comparative results of phase III clinical trials and quality characteristics between biosimilars and their originators; the results of clinical studies on switching from originators to their biosimilars; and a comparison of the estimated cost on patients in consideration of the high medical cost payment system. Priority differed depending on the studied disease areas. In terms of post-marketing information, physicians requested a variety of information. When explaining biosimilars to the patients, physicians would like to use general material from government describing the comparability between originators and their biosimilars. These results suggest that physicians sought more comparative information on the quality, efficacy, and patients' cost between originators and their biosimilars when adopting or prescribing biosimilars.Keywords
This publication has 12 references indexed in Scilit:
- Biosimilar Perceptions Among Healthcare Professionals and Commercial Medical Benefit Policy Analysis in the United StatesBioDrugs, 2021
- European Stakeholder Learnings Regarding Biosimilars: Part I—Improving Biosimilar Understanding and AdoptionBioDrugs, 2020
- Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA StudyBioDrugs, 2020
- Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?Frontiers in Pharmacology, 2020
- Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel DiseaseDigestive Diseases and Sciences, 2020
- Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical CentreJournal of Crohn's and Colitis, 2020
- Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group studyArthritis Research & Therapy, 2019
- Academic oncology clinicians’ understanding of biosimilars and information needed before prescribingTherapeutic Advances in Medical Oncology, 2019
- Factors Affecting Health Care Provider Knowledge and Acceptance of Biosimilar Medicines: A Systematic ReviewJournal of Managed Care & Specialty Pharmacy, 2019
- Does Use of a Biosimilar Product Reduce the Expenditure of Patients?Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2016